TheraRadar
← Back
Data updated: Jun 28, 2026

MARTEC USA LLC

Generics

MARTEC USA LLC is a generic drug manufacturer focused on Cardiovascular.

2004
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

MARTEC USA LLC's Key Drugs

MARTEC USA LLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MARTEC USA LLC's Recent FDA Approvals

New NDA/BLA approvals for MARTEC USA LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MARTEC USA LLC's Therapeutic Areas

MARTEC USA LLC's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%
1 drugs

MARTEC USA LLC's Top Competitors

MARTEC USA LLC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

MARTEC USA LLC Pipeline Snapshot

Active clinical trials for MARTEC USA LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling